Biogen Stays Flat Despite Positive 128-Week Aduhelm Data

Biogen shares dipped 2% then bounced back 5% this week after the company on Wednesday presented long-term Phase III data of its controversial yet approved Alzheimer’s disease drug Aduhelm (aducanumab) at AD/PD 2022. After 128 weeks of treatment, patients in the long-term extension…

Source: www.genengnews.com – Read more